MedTrace Logo

Neutralizing Interferon Type 1 in Hidradenitis Suppurativa

NCT07067099 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-07-16

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer anti-IFN-1 autoantibodies.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

BIOLOGICAL

Plasma with neutralizing autoantibodies to Type I Interferons

Transfusion of one unit of plasma containing high titre anti-IFN-1 autoantibodies

Sponsors & Collaborators

  • Etablissement Français du Sang

    collaborator OTHER

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07067099 on ClinicalTrials.gov